https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: report of 5 cases and literature review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29675 Wed 02 Mar 2022 14:26:49 AEDT ]]> Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10953 1.2 (abnormal) on admission, and the remaining 28 had an INR > 1.2 within 12 hours of the bite. Of 33 patients with myotoxicity, a combination of CK > 250 U/L and an abnormal aPTT identified all but two cases by 12 hours; one of these two was identified within 12 hours by leukocytosis. Nine cases of isolated neurotoxicity had a median time of onset after the bite of 4 hours (range, 35 min - 12 h). The combination of serial INR, aPTT and CK tests and repeated neurological examination identified 213 of 222 severe envenoming cases (96%) by 6 hours and 238 of 240 (99%) by 12 hours. Conclusion: Laboratory parameters (INR, aPTT and CK) and neurological reassessments identified nearly all severe envenoming cases within 12 hours of the bite, even in this conservative analysis that assumed normal test results if the test was not done.]]> Sat 24 Mar 2018 08:14:15 AEDT ]]> Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45844 20 x 109/L, and avoidance of severe bleeding. Steroids are the standard first line treatment, with either 6-week courses of tapering prednisone or repeated courses of high dose dexamethasone providing equivalent efficacy. Intravenous immunoglobulin can be used periprocedurally or as first line therapy in combination with steroids. Changes in management as a result of this statement: There is no consensus on choice of second line treatments. Options with the most robust evidence include splenectomy, rituximab and thrombopoietin receptor agonists. Other therapies include azathioprine, mycophenolate mofetil, dapsone and vinca alkaloids. Given that up to one-third of patients achieve a satisfactory haemostatic response, splenectomy should be delayed for at least 12 months if possible. In life-threatening bleeding, we recommend platelet transfusions to achieve haemostasis, along with intravenous immunoglobulin and high dose steroids.]]> Mon 07 Nov 2022 14:17:09 AEDT ]]>